203 related articles for article (PubMed ID: 21771831)
1. Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care.
Rodríguez LA; Cea-Soriano L; Martín-Merino E; Johansson S
BMJ; 2011 Jul; 343():d4094. PubMed ID: 21771831
[TBL] [Abstract][Full Text] [Related]
2. Association between low-dose acetylsalicylic acid reinitiation and the risk of myocardial infarction or coronary heart disease death.
Sáez ME; González-Pérez A; Johansson S; Himmelmann A; García Rodríguez LA
Eur J Prev Cardiol; 2016 Jul; 23(10):1029-36. PubMed ID: 26603743
[TBL] [Abstract][Full Text] [Related]
3. Use of proton pump inhibitors and the risk of coronary events in new users of low-dose acetylsalicylic acid in UK primary care.
García Rodríguez LA; Johansson S; Nagy P; Cea Soriano L
Thromb Haemost; 2014 Jan; 111(1):131-9. PubMed ID: 24153412
[TBL] [Abstract][Full Text] [Related]
4. Role of antiplatelet drugs in the prevention of cardiovascular events.
Tendera M; Wojakowski W
Thromb Res; 2003 Jun; 110(5-6):355-9. PubMed ID: 14592562
[TBL] [Abstract][Full Text] [Related]
5. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Ikeda Y; Shimada K; Teramoto T; Uchiyama S; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Ishizuka N
JAMA; 2014 Dec; 312(23):2510-20. PubMed ID: 25401325
[TBL] [Abstract][Full Text] [Related]
6. Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations.
Timmis A; Rapsomaniki E; Chung SC; Pujades-Rodriguez M; Moayyeri A; Stogiannis D; Shah AD; Pasea L; Denaxas S; Emmas C; Hemingway H
BMJ; 2016 Jun; 353():i3163. PubMed ID: 27334486
[TBL] [Abstract][Full Text] [Related]
7. Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.
Harris J; Pouwels KB; Johnson T; Sterne J; Pithara C; Mahadevan K; Reeves B; Benedetto U; Loke Y; Lasserson D; Doble B; Hopewell-Kelly N; Redwood S; Wordsworth S; Mumford A; Rogers C; Pufulete M
Health Technol Assess; 2023 May; 27(8):1-257. PubMed ID: 37435838
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Roshandel G; Khoshnia M; Poustchi H; Hemming K; Kamangar F; Gharavi A; Ostovaneh MR; Nateghi A; Majed M; Navabakhsh B; Merat S; Pourshams A; Nalini M; Malekzadeh F; Sadeghi M; Mohammadifard N; Sarrafzadegan N; Naemi-Tabiei M; Fazel A; Brennan P; Etemadi A; Boffetta P; Thomas N; Marshall T; Cheng KK; Malekzadeh R
Lancet; 2019 Aug; 394(10199):672-683. PubMed ID: 31448738
[TBL] [Abstract][Full Text] [Related]
9. Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).
Stefanescu Schmidt AC; Kereiakes DJ; Cutlip DE; Yeh RW; D'Agostino RB; Massaro JM; Hsieh WH; Mauri L;
Circulation; 2017 May; 135(18):1720-1732. PubMed ID: 28228427
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular and upper gastrointestinal bleeding consequences of low-dose acetylsalicylic acid discontinuation.
Cea Soriano L; Bueno H; Lanas A; García Rodríguez LA
Thromb Haemost; 2013 Dec; 110(6):1298-304. PubMed ID: 24008261
[TBL] [Abstract][Full Text] [Related]
11. Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54).
Bonaca MP; Goto S; Bhatt DL; Steg PG; Storey RF; Cohen M; Goodrich E; Mauri L; Ophuis TO; Ruda M; Špinar J; Seung KB; Hu D; Dalby AJ; Jensen E; Held P; Morrow DA; Braunwald E; Sabatine MS
Circulation; 2016 Sep; 134(12):861-71. PubMed ID: 27576775
[TBL] [Abstract][Full Text] [Related]
12. A prospective study of aspirin use and primary prevention of cardiovascular disease in women.
Manson JE; Stampfer MJ; Colditz GA; Willett WC; Rosner B; Speizer FE; Hennekens CH
JAMA; 1991 Jul 24-31; 266(4):521-7. PubMed ID: 2061978
[TBL] [Abstract][Full Text] [Related]
13. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Mehta SR; Yusuf S; Peters RJ; Bertrand ME; Lewis BS; Natarajan MK; Malmberg K; Rupprecht H; Zhao F; Chrolavicius S; Copland I; Fox KA;
Lancet; 2001 Aug; 358(9281):527-33. PubMed ID: 11520521
[TBL] [Abstract][Full Text] [Related]
14. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.
BMJ; 1994 Jan; 308(6921):81-106. PubMed ID: 8298418
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.
Jones WS; Mulder H; Wruck LM; Pencina MJ; Kripalani S; Muñoz D; Crenshaw DL; Effron MB; Re RN; Gupta K; Anderson RD; Pepine CJ; Handberg EM; Manning BR; Jain SK; Girotra S; Riley D; DeWalt DA; Whittle J; Goldberg YH; Roger VL; Hess R; Benziger CP; Farrehi P; Zhou L; Ford DE; Haynes K; VanWormer JJ; Knowlton KU; Kraschnewski JL; Polonsky TS; Fintel DJ; Ahmad FS; McClay JC; Campbell JR; Bell DS; Fonarow GC; Bradley SM; Paranjape A; Roe MT; Robertson HR; Curtis LH; Sharlow AG; Berdan LG; Hammill BG; Harris DF; Qualls LG; Marquis-Gravel G; Modrow MF; Marcus GM; Carton TW; Nauman E; Waitman LR; Kho AN; Shenkman EA; McTigue KM; Kaushal R; Masoudi FA; Antman EM; Davidson DR; Edgley K; Merritt JG; Brown LS; Zemon DN; McCormick TE; Alikhaani JD; Gregoire KC; Rothman RL; Harrington RA; Hernandez AF;
N Engl J Med; 2021 May; 384(21):1981-1990. PubMed ID: 33999548
[TBL] [Abstract][Full Text] [Related]
16. Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
Parker WA; Storey RF
Heart; 2016 May; 102(10):783-9. PubMed ID: 26857211
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of high- versus low-dose aspirin after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
Yu J; Mehran R; Dangas GD; Claessen BE; Baber U; Xu K; Parise H; Fahy M; Lansky AJ; Witzenbichler B; Grines CL; Guagliumi G; Kornowski R; Wöhrle J; Dudek D; Weisz G; Stone GW
JACC Cardiovasc Interv; 2012 Dec; 5(12):1231-8. PubMed ID: 23257371
[TBL] [Abstract][Full Text] [Related]
18. Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluation.
Mackenzie IS; Hawkey CJ; Ford I; Greenlaw N; Pigazzani F; Rogers A; Struthers AD; Begg AG; Wei L; Avery AJ; Taggar JS; Walker A; Duce SL; Barr RJ; Dumbleton JS; Rooke ED; Townend JN; Ritchie LD; MacDonald TM;
Health Technol Assess; 2024 Mar; 28(18):1-55. PubMed ID: 38551218
[TBL] [Abstract][Full Text] [Related]
19. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.
Sanmuganathan PS; Ghahramani P; Jackson PR; Wallis EJ; Ramsay LE
Heart; 2001 Mar; 85(3):265-71. PubMed ID: 11179262
[TBL] [Abstract][Full Text] [Related]
20. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Antithrombotic Trialists' Collaboration
BMJ; 2002 Jan; 324(7329):71-86. PubMed ID: 11786451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
